dalcetrapib
Sponsors
Hoffmann-La Roche, DalCor Pharmaceuticals
Conditions
Acute Coronary SyndromeCardiovascular DiseaseCardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)Coronary Heart DiseaseCovid19DyslipidemiaHealthy Volunteer
Phase 1
Phase 2
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
CompletedNCT00353522
Start: 2006-07-31End: 2008-10-31Updated: 2020-01-27
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
CompletedNCT00655538
Start: 2008-02-29End: 2010-05-31Updated: 2020-01-02
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
CompletedNCT00697203
Start: 2005-07-31End: 2006-05-31Updated: 2020-01-02
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
CompletedNCT04676867
Start: 2021-01-11End: 2021-05-17Updated: 2022-12-07
Phase 3
A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
TerminatedNCT01059682
Start: 2010-01-31End: 2011-09-30Updated: 2020-03-24
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
CompletedNCT01323153
Start: 2011-03-31End: 2012-03-31Updated: 2019-07-30
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
CompletedNCT01516541
Start: 2012-01-31End: 2012-07-31Updated: 2016-11-02
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
CompletedNCT02525939
Start: 2016-04-30End: 2021-10-31Updated: 2022-10-12
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
RecruitingNCT05918861
Start: 2023-10-03End: 2027-08-01Target: 2000Updated: 2026-06-22